Vitamin D Research

back to research menu

Miscellaneous

• Vitamin D insufficiency underlies unexpected hypocalcemia following high dose glucocorticoid therapy. Bone. In Press, Available online 2007.09.22.
• Can vitamin d reduce total mortality? Arch Intern Med. 2007 Sep 10;167(16):1709–10.
• Effects of parathyroidectomy on bone remodeling markers and vitamin D status in patients with chronic kidney disease‑mineral and bone disorder. Int Urol Nephrol. Epub 2007.08.07.
• 25‑Hydroxyvitamin D levels and albuminuria in the Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis. 2007 Jul;50(1):69–77.
• Changes in serum 25‑hydroxyvitamin D and plasma intact PTH levels following treatment with ergocalciferol in patients with CKD. Am J Kidney Dis. 2007 Jul;50(1):59–68.
• Expanding Role for Vitamin D in Chronic Kidney Disease: Importance of Blood 25‑OH‑D Levels and Extra‑Renal 1alpha‑Hydroxylase in the Classical and Nonclassical Actions of 1alpha,25‑Dihydroxyvitamin D(3). Semin Dial. 2007 Jul;20(4):316–324.
• What is new in vitamin D: 2006–2007. Curr Opin Rheumatol. 2007 Jul;19(4):383–8.
• Identification and functional characterization of a novel mutation in the calcium‑sensing receptor gene in familial hypocalciuric hypercalcemia: modulation of clinical severity by vitamin D status. J Clin Endocrinol Metab. 2007 Jul;92(7):2616–23.
• Vitamin D status modulates the immune response to Epstein Barr virus: Synergistic effect of risk factors in multiple sclerosis. Med Hypotheses. Epub 2007.06.13.
• Seasonality of month of birth of patients with Graves' and Hashimoto's diseases differ from that in the general population. Eur J Endocrinol. 2007 Jun;156(6):631–6.
• Asymptomatic rickets in adolescent girls. Indian J Pediatr. 2007 Jun;74(6):571–5.
• Calcium Plus Vitamin D Supplementation and the Risk of Postmenopausal Weight Gain. Arch Intern Med. 2007 May 14;167:893‑902.
• Cholecalciferol significantly increases 25‑hydroxyvitamin D concentrations in adults with cystic fibrosis. AJCN, Vol. 85, No. 5, 1307–1311, May 2007
• Association Between Vitamin D and Age‑Related Macular Degeneration in the Third National Health and Nutrition Examination Survey, 1988 Through 1994. Arch Ophthalmol. 2007 May;125:661–669.
• Effect of 2‑Methylene‑19‑nor‑(20S)‑1alpha‑Hydroxy‑ Bishomopregnacalciferol (2MbisP), an Analog of Vitamin D, on Secondary Hyperparathyroidism. J Bone Miner Res. 2007 May;22(5):686–94.
• Elevated blood lead concentrations and vitamin D deficiency in winter and summer in young urban children. Environ Health Perspect. 2007 Apr;115(4):630–5.
• Successful treatment of refractory warts with topical vitamin D(3) derivative (maxacalcitol, 1alpha, 25‑dihydroxy‑22‑oxacalcitriol) in 17 patients. J Dermatol. 2007 Apr;34 (4):264–6.
• Treatment of pigmented lesions of neurofibromatosis 1 with intense pulsed‑radio frequency in combination with topical application of vitamin D(3) ointment. J Dermatol. 2007 Apr;34 (4):227–30.
• Role of nuclear hormone receptors in butyrate‑mediated up‑regulation of the antimicrobial peptide cathelicidin in epithelial colorectal cells. Molecular Immunology Volume 44, Issue 8, March 2007, Pages 2107–2114.
• Prevalence of vitamin D deficiency rickets in adolescent school girls in Western region, Saudi Arabia. Saudi Med J. 2007 Mar;28(3):441–4.
• Drug insight: vitamin D analogs in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease. Nat Clin Pract Endocrinol Metab. 2007 Feb;3(2):134–44. Review.
• In vivo effects of chronic contamination with depleted uranium on vitamin D(3) metabolism in rat. Biochim Biophys Acta. 2007 Feb;1770(2):266–72.
• Age‑related alteration of 1alpha,25(OH)(2)‑vitamin D (3)‑dependent activation of p38 MAPK in rat intestinal cells. Biogerontology. 2007 Feb;8(1):13–24.
• Vitamin D and vascular calcification. Curr Opin Lipidol. 2007 Feb;18(1):41–6.
• Inhibition of prostate growth and inflammation by the vitamin D receptor agonist BXL‑628 (elocalcitol). J Steroid Biochem Mol Biol. Epub 2007.01.19.
• Vitamin D and Parathyroid Hormone in Outpatients With Noncholestatic Chronic Liver Disease. Clin Gastroenterol Hepatol. Epub 2007.01.09.
• 1,25‑Dihydroxyvitamin D(3) regulates genes responsible for detoxification in intestine. Toxicol Appl Pharmacol. 2007 Jan 1;218(1):37–44.
• 25‑Hydroxyvitamin D, insulin resistance, and kidney function in the Third National Health and Nutrition Examination Survey. Kidney Int. 2007 Jan;71(2):134–9.
• Nutritional vitamin D deficiency presenting as hemichorea. J Child Neurol. 2007 Jan;22(1):74–6.
• Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease. Am J Nephrol. 2007;27(1):36–43.
• Severe vitamin D deficiency in chronic renal failure patients on peritoneal dialysis. Clin Nephrol. 2006 Oct;66(4):247–55.
• Comparison of the efficacy of calcipotriol and maxacalcitol in combination with narrow‑band ultraviolet B therapy for the treatment of psoriasis vulgaris. Photodermatol Photoimmunol Photomed. 2006 Oct;22(5):262–4.
• Evidence for involvement of the vitamin D receptor gene in idiopathic short stature via a genome‑wide linkage study and subsequent association studies. Hum Mol Genet. 2006 Sep 15;15(18):2772–83.
• Epidemic influenza and vitamin D. Epidemiol Infect. 2006 Sep 7;1–12
• Antiepileptic drugs and bone metabolism. Nutr Metab (Lond). 2006 Sep 6;3(1):36
• Vitamin D Metabolism in Peripheral Blood Mononuclear Cells Is Influenced by Chewing "Betel Nut" (Areca catechu) and Vitamin D Status. Journal of Clinical Endocrinology & Metabolism Vol. 91, No. 7 2612–2617.
• Chronic contamination with 137Cesium affects Vitamin D3 metabolism in rats. Toxicology. 2006 Aug 1;225(1):75–80.
• Effects of depleted uranium after short‑term exposure on vitamin D metabolism in rat. Arch Toxicol. 2006 Aug;80(8):473–480.
• Role of phosphorus and vitamin D analogs in the pathogenesis of vascular calcification. J Pharmacol Exp Ther. 2006 Jul;318(1):90–8.
• Vitamin D and African Americans. J Nutr. 2006 Apr;136(4):1126–9.
• Oral treatment with a vitamin D3 analogue (BXL628) has anti‑inflammatory effects in rodent model of interstitial cystitis. BJU International Volume 97 Page 617—March 2006
• Toll‑like receptor triggering of a vitamin D‑mediated human antimicrobial response. Science. 2006 Mar 24;311(5768):1770–3.
• Steroid and xenobiotic receptor and vitamin D receptor crosstalk mediates CYP24 expression and drug‑induced osteomalacia J Clin Invest. 116:1703–1712 (2006) March.
• The preventive effect of vitamin D3 on radiation‑induced hair toxicity in a rat model. Life Sci. 2006 Feb 28;78(14):1646–51.
• Association between vitamin D receptor, CCR5, TNF‑alpha and TNF‑beta gene polymorphisms and HBV infection and severity of liver disease. J Hepatol. Epub 2006.02.21.
• Increased severity of chemically induced seizures in mice with partially deleted Vitamin D receptor gene. Neurosci Lett. 2006 Feb 6;394(1):69–73.
• Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation. Kidney Int. 2006 Jan;69(1):33–43. Review.
• Epilepsy‑related injuries. Epilepsia. 2006;47 Suppl 1:79–86. Review.
• Relationship between serum 25‑hydroxyvitamin d and pulmonary function in the third national health and nutrition examination survey. Chest. 2005 Dec;128(6):3792–8.
• Vitamin D deficiency among patients attending a central New Zealand rheumatology outpatient clinic. N Z Med J. 2005 Nov 11;118(1225):U1727.
• Vitamin D and its analogues: do they protect against cardiovascular disease in patients with kidney disease? Kidney Int. 2005 Nov;68(5):1973–81. Review.
• Vitamin D: important for prevention of osteoporosis, cardiovascular heart disease, type 1 diabetes, autoimmune diseases, and some cancers. South Med J. 2005 Oct;98(10):1024–7. Review.
• Immunoregulation by 1,25‑dihydroxyvitamin D3: basic concepts. J Steroid Biochem Mol Biol. 2005 Oct;97(1–2):93–101. Review.
• Anticonvulsant effects of 1,25‑dihydroxyvitamin D in chemically induced seizures in mice. Brain Res Bull. 2005 Sep 30;67(1–2):156–60.
• The role of vitamin D in vascular calcification in chronic kidney disease. Semin Dial. 2005 Jul–Aug;18(4):307–14. Review.
• Vitamin D for health and in chronic kidney disease. Semin Dial. 2005 Jul–Aug;18(4):266–75. Review.
• Vitamin‑D receptor (VDR) gene (Fok‑I, Taq‑I and Apa‑I) polymorphisms in healthy individuals from north Indian population. Asian Pac J Cancer Prev. 2005 Apr–Jun;6(2):147–52.
• Vitamin D: a hormone for all seasons—how much is enough? Clin Biochem Rev. 2005 Feb;26(1):21–32.
• Tanning is associated with optimal vitamin D status (serum 25‑hydroxyvitamin D concentration) and higher bone mineral density. Am J Clin Nutr. 2004 Dec;80(6):1645–9.
• Association of subclinical vitamin D deficiency with severe acute lower respiratory infection in Indian children under 5 y. Eur J Clin Nutr. 2004 Apr;58(4):563–7.
• Serum levels of prostate‑specific antigen and vitamin D in peritoneal dialysis patients. Adv Perit Dial. 2004;20:203–8.
• Does vitamin D administered to children with asthma treated with inhaled glucocorticoids affect short‑term growth or bone turnover? Pediatr Pulmonol. 2003 Nov;36(5):399–404.
• Altered gene expression profile in the kidney of vitamin D receptor knockout mice. J Cell Biochem. 2003 Jul 1;89(4):709–19.
• Vitamin D supplementation to healthy children does not affect serum osteocalcin or markers of type I collagen turnover. Acta Paediatr. 2003 Jul;92(7):797–801.
• Vitamin D3 in patients with various grades of chronic pancreatitis, according to morphological and functional criteria of the pancreas. Dig Dis Sci. 2003 Mar;48(3):533–8.
• Season modifies the relationship between bone and blood lead levels: the Normative Aging Study. Arch Environ Health. 2002 Sep–Oct;57(5):466–72.
• Renal failure and vitamin D. Clin Calcium. 2002 Jun;12(6):711–23. In Japanese.
• Bone mineral density, biochemical markers of bone turnover, and hormonal status in men with systemic lupus erythematosus. Rheumatol Int. 2001 Nov;21(3):97–102.
• Seasonal variation in cause‑specific mortality: are there high‑risk groups? 25‑year follow‑up of civil servants from the first Whitehall study. Int J Epidemiol. 2001 Oct;30(5):1109–16.
• Serum 25‑hydroxyvitamin D and parathyroid hormone in patients with ankylosing spondylitis before and after a three‑week rehabilitation treatment at high altitude during winter and spring. Wien Klin Wochenschr. 2001 Apr 30;113(9):328–32.
• Vitamin D analogs: perspectives for treatment. Miner Electrolyte Metab. 1999 Jul–Dec;25(4–6):337–41. Review.
• Osteoporosis in adult patients with celiac disease. Bone. 1999 Mar;24(3):249–55.
• Measurement of vitamin D3 metabolites in smelter workers exposed to lead and cadmium. Occup Environ Med. 1998 Jul;55(7):446–52.
• Decreased serum concentrations of 1,25(OH)2‑vitamin D3 in patients with gout. Metabolism. 1998 Mar;47(3):336–8.
• Saccharated ferric oxide (SFO)‑induced osteomalacia: in vitro inhibition by SFO of bone formation and 1,25‑dihydroxy‑vitamin D production in renal tubules. Bone. 1997 Jul;21(1):57–64.
• Metabolic bone disease in black teenagers with genu valgum or varum without radiologic rickets: a bone histomorphometric study. J Bone Miner Res. 1994 Apr;9(4):479–86.
• Low serum vitamin D metabolites in women with rheumatoid arthritis. Scand J Rheumatol. 1993;22(4):172–7.
• Psoriasis and vitamin D3. A review of our experience. Arch Dermatol. 1989 Feb;125(2):231–4.
• Skin as the site of vitamin D synthesis and target tissue for 1,25‑dihydroxyvitamin D3. Use of calcitriol (1,25‑dihydroxyvitamin D3) for treatment of psoriasis. Arch Dermatol. 1987 Dec;123(12):1677–1683a. Review.
• Influence of cadmium on the metabolism of vitamin D3 in rats. Toxicol Appl Pharmacol. 1987 Jun 30;89(2):158–64.
• 1,25‑Dihydroxyvitamin D3 treatment results in increased choline acetyltransferase activity in specific brain nuclei. Endocrinology. 1986 Apr;118(4):1433–9.
• Vitamin D metabolites in idiopathic infantile hypercalcaemia. Arch Dis Child. 1985 Dec;60(12):1140–3.
• Low serum concentrations of 1,25‑dihydroxyvitamin D in human magnesium deficiency. J Clin Endocrinol Metab. 1985 Nov;61(5):933–40.
• Magnesium administration reverses the hypocalcaemia secondary to hypomagnesaemia despite low circulating levels of 25‑hydroxyvitamin D and 1,25‑dihydroxyvitamin D. Clin Endocrinol (Oxf). 1985 Jun;22(6):807–15.
• Vitamin D deficiency and otosclerosis. Otolaryngol Head Neck Surg. 1985 Jun;93(3):313–21.
• Low serum 25‑hydroxyvitamin D in hereditary hemochromatosis: relation to iron status. Gastroenterology. 1985 Apr;88(4):865–9.
• Administration of 1,25‑dihydroxyvitamin D3 results in the elevation of hippocampal seizure threshold levels in rats. Brain Res. 1984 Apr 23;298(1):125–9.
• Measurement of vitamin D metabolites in anephric subjects. Nephron. 1984;36(4):230–4.
• The role of season in the epidemiology of influenza. J Hyg (Lond). 1981 Feb;86(1):35–47.
• A case of hypoparathyroidism in a child with beta‑thalassemia successfully treated with 1 alpha‑hydroxy‑vitamin D3. Helv Paediatr Acta. 1981;36(2):171–3.
• Vitamin D metabolism in hypoparathyroidism. J Clin Endocrinol Metab. 1980 Sep;51(3):606–10.
• Case report: hypoparathyroidism and iron storage disease. Treatment with 25‑hydroxyvitamin D3. Am J Med Sci. 1978 Nov–Dec;276(3):363–8.
• 1alpha‑hydroxycholecalciferol in the treatment of hypoparathyroidism. Acta Med Scand. 1977 Jan;201(1–2):3–7.
• Treatment of hypoparathyroidism with 1,25‑dihydroxycholecalciferol. Clin Endocrinol (Oxf). 1976;5 Suppl:167S–173S.
• "Anticonvulsant action" of vitamin D in epileptic patients? A controlled pilot study. Br Med J. 1974 May 4;2(5913):258–9.

back to research menu